ReviewAAPS PharmSciTech2026
Structurally Modified Cyclodextrins in Topical Nanotechnology: Advancing Barrier-Penetrating Drug Delivery Strategies for Psoriasis Management.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intelligent Diagnosis and Treatment of Psoriasis Research: A Bibliometric Analysis from 2005-01-01 to 2025-12-31.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory skin condition characterized by the hyperproliferation of keratinocytes that results in erythematous and scaly plaques on the epidermal surface. Conventional therapeutic approaches exhibit drawbacks such as inadequate skin penetration, low drug bioavailability, and undesirable side effects. Nanoformulations emerge as a novel strategy to enhance drug delivery for treating psoriatic lesions with modified cyclodextrins (CDs), offering significant potential to improve their efficacy in the field of medicine. Cyclodextrins are well-known as versatile excipients that improve solubility, dissolution rate, chemical stability, and bioavailability through the formation of inclusion complexes. Furthermore, the chemical modifications of cyclodextrins such as sulfation, methylation, and hydroxypropylation have further enhanced their utility in topical formulations. Modified cyclodextrins enhance the delivery of anti-psoriatic agents such as TNF-α or IL-17 inhibitors and target key inflammatory pathways in psoriasis while reducing systemic exposure and minimizing side effects like immunosuppression, infections, and gastrointestinal disturbances. Additionally, modified cyclodextrins help to repair the epidermal barrier by increasing the efficacy of anti-inflammatory and keratinocyte-modulating medications. This article highlights the capabilities of modified cyclodextrins for revolutionizing the transformation of more effective and targeted therapies for psoriasis by identifying the limitations of current therapies and exploring the innovative applications of modified cyclodextrins in nanoformulations.
Indexed as
Identifiers
41578094What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.